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Intrinsically disordered proteins participate in many important cellular regulatory processes. The
absence of a well-deﬁned structure in the free state of a disordered domain, and even on occasion
when it is bound to physiological partners, is fundamental to its function. Disordered domains are
frequently the location of multiple sites for post-translational modiﬁcation, the key element of
metabolic control in the cell. When a disordered domain folds upon binding to a partner, the result-
ing complex buries a far greater surface area than in an interaction of comparably-sized folded pro-
teins, thus maximizing speciﬁcity at modest protein size. Disorder also maintains accessibility of
sites for post-translational modiﬁcation. Because of their inherent plasticity, disordered domains
frequently adopt entirely different structures when bound to different partners, increasing the
repertoire of available interactions without the necessity for expression of many different proteins.
This feature also adds to the faithfulness of cellular regulation, as the availability of a given disor-
dered domain depends on competition between various partners relevant to different cellular
processes.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It has been two decades since the ﬁrst descriptions [1,2] of the
functional importance of protein disorder [3–5], and in that time a
vast new research area has developed to elucidate the complex
mechanisms by which the enigmatic disordered proteins perform
their cellular roles. Early work in the ﬁeld coincided with signiﬁ-
cant advances in bioinformatics and genome sequencing, revealing
the prevalence of disorder in the eukaryotic proteome. Notably,
nearly half of the eukaryotic proteome was found to contain
regions of 40 or more amino acid residues predicted to be disor-
dered under physiological conditions [3], and a substantial propor-
tion of these proteins containing disordered regions are involved in
cellular regulation and signaling processes [6].
Disordered sequences are generally characterized by low
sequence complexity and biased amino acid composition. Bulky
hydrophobic amino acids are typically present in low abundance,
while charged and hydrophilic amino acids are often overrepre-
sented in disordered segments [7]. Intrinsically disordered protein
(IDPs) can be entirely disordered polypeptides, or they can contain
a combination of disordered regions (IDRs) and structured domains[8], with the latter being a common characteristic of eukaryotic
proteins.
The physical features of IDPs make them well suited for regula-
tory and signaling processes [9,10]. In isolation, IDPs do not adopt
well-formed, stable globular structures and instead dynamically
sample a range of conformational states. These states can vary
from fully extended polypeptide chains to collapsed globules. In
their unbound states, IDPs are highly ﬂexible, allowing for exten-
sive conformational sampling. The inherent ﬂexibility of IDPs
allows for a degree of promiscuity in interactions with cellular
partners—when an IDP is in its free state, it is available for interac-
tion with a wide array of macromolecular targets [10]. The
dynamic nature of most IDPs, which sample extended as well as
more compact states, allows for increased availability of binding
sites as well as unrestricted access to sites of post-translational
modiﬁcation [11].
Indeed, many IDPs have been identiﬁed as ‘molecular hubs’
inside the cell, consistent with their numerous roles in cellular
processes, and much of our knowledge about IDPs comes from
studies of their interactions with other proteins or nucleic acids
[7,10,12]. Upon binding to cellular targets, many IDPs undergo a
disorder-to-order transition to form well-deﬁned structures while
in complex with their targets. IDPs can bind to their molecular tar-
gets in many ways. Some IDPs bind to their targets in partially
extended structures, burying large surface areas to counteract
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bind through localized motifs, with relatively small binding inter-
faces. Many IDPs contain multiple interaction motifs, and can bind
to multiple cellular partners to form higher order macromolecular
assemblies.
It is important to note that complexes involving IDPs are often
highly dynamic and short lived, a result of the ﬂexibility encoded
by the IDP sequence itself. IDPs often participate in interactions
with high speciﬁcity but low afﬁnity ( lM range), facilitating
rapid exchange of binding sites between multiple interacting part-
ners. Recognition of binding partners often occurs through short,
linear sequence motifs [13–15], with regions of the IDP outside
these motifs remaining largely disordered, leading to the formation
of so-called ’fuzzy complexes’ [16,17]. The conformational equilib-
ria present in even the bound states of IDPs allows IDPs to be pleio-
tropic binding partners in the cell [18] and underlies their critical
roles in regulatory processes.
In this review, we will highlight a few of the properties that
make IDPs extremely well suited to their roles in cellular regula-
tion and signaling. Speciﬁcally, we will focus on how IDPs use
short, conserved sequence motifs to recognize their binding
partners and facilitate binding interactions; how the dynamic
properties of IDPs in both their free states and in complex enable
a single IDP to interact with numerous cellular partners; and
how post-translational modiﬁcations can dramatically alter the
conformational ensembles and cellular behavior of IDPs. Through
this lens, we will examine how IDPs use their dynamic properties
to their advantage to carry out their numerous functions in the cell.
2. IDPs contain multiple interaction sites
Given the well-established biological signiﬁcance of IDPs, it is
important to obtain a better understanding of the detailed mecha-
nisms by which IDPs recognize and bind their targets. IDPs often
utilize short peptide motifs to interact with their cellular targets.
These motifs can be of many forms, but the peptide motifs most
commonly utilized by IDPs fall into two groups: short, linear
sequence motifs, and amphipathic, disordered sequences that
adopt structure upon binding [13]. Peptide motifs are also common
sites for post-translational modiﬁcations, the importance of which
will be discussed later in this review.
An IDP may rely on one peptide motif for binding, or it may uti-
lize several motifs in tandem to form a stable, high afﬁnity com-
plex with one or more interacting partners. Bioinformatics
approaches as well as mutational studies have identiﬁed a number
of peptide motifs that play important roles in driving interactions
between IDPs and their targets [13]. Speciﬁc recognition sequences
within IDPs are often conserved between organisms and play a
major role in determining the functional binding partners of an
IDP.
2.1. Linear motifs
IDPs often utilize short linear sequence motifs (commonly
referred to as SLiMs; also called eukaryotic linear motifs, ELMs)
to form localized interactions with their molecular partners
[13,15,19,20]. Identiﬁcation of linear motifs by bioinformatic
approaches is technically difﬁcult and much of the information
about these short peptide motifs, as well as validation of their bio-
logical functions, has been obtained experimentally [20].
Nonetheless, comparisons of motifs from the literature and the
online ELM database [21] reveal some interesting features that
shed light on the binding mechanisms of IDPs. Most linear motifs
are shorter than 10 amino acids in length, monopartite, and partic-
ipate in transient interactions with low micromolar afﬁnities
[12,15]. Multiple linear motifs can function synergistically toincrease the binding afﬁnity of an IDP and its target protein [15].
The functional importance of these linear motifs can be readily
linked to their evolutionary characteristics, as many linear motifs
have been identiﬁed through comparison of sequences that encode
proteins with functional similarities. Due to the short length of
these motifs, a single point mutation could be sufﬁcient to disrupt
molecular recognition. Thus, evolutionary conservation of short
sequence motifs frequently implies functional importance [19].
An excellent example of a conserved linear motif playing an
important functional role in biology can be found in the viral gen-
ome. The oncoprotein E7 from the human papilloma virus (HPV)
interacts with both the TAZ2 domain of the transcriptional coacti-
vators CBP/p300 and the pocket domain of the retinoblastoma pro-
tein pRb to deregulate the cell cycle of the host organism and
enable cellular transformation [22]. E7 interacts with its cellular
partners via its intrinsically disordered N-terminus, which contains
two conserved regions, CR1 and CR2 [23]. The CR2 region contains
a conserved LxCxE motif that is shared amongst several viral onco-
proteins, including the T antigen of SV40 and the adenoviral pro-
tein E1A [24]. Mutation or deletion of the LxCxE motif abolishes
binding to pRb, conﬁrming that the LxCxE motif plays a critical role
in determining the oncogenic potential of these viruses [22]. In the
case of E7, the LxCxE motif also participates in interactions with
the TAZ2 domain of the general transcriptional coactivator CBP
and its paralog p300 [23]. For cellular transformation by high risk
strains of HPV, E7 must utilize the LxCxE motif to interact with
both TAZ2 and pRb. To accomplish this, E7 dimerizes through a
third conserved region at its C-terminus to enable simultaneous
binding to TAZ2 and pRb through the LxCxE motif [23].
Dimerization of E7 allows tandem interactions with CBP/p300
and pRb, promoting acetylation of pRb by the HAT domain of
CBP/p300 and disruption of cell cycle control [23].
2.2. Molecular recognition features
In addition to linear motifs, IDPs frequently feature sequences
that play important roles in molecular recognition but also
undergo disorder-to-order transitions upon complex formation.
These elements, often called molecular recognition features
(MoRFs), are prevalent in IDPs and have been shown to mediate
interactions between ordered and disordered proteins involved in
cellular signaling and regulation [25,26]. Recognition elements
have been identiﬁed to include all of the secondary structural ele-
ments, though recognition elements that form helices upon bind-
ing are by far the most widely described in the literature
[10,15,25].
Like linear motifs, molecular recognition elements typically
participate in moderate afﬁnity but high speciﬁcity interactions
with their molecular targets. Upon recognizing their targets, many
IDPs undergo coupled folding and binding processes to adopt
stable structures in complex [12]. Often, a single molecular recog-
nition element is capable of interacting with multiple targets, and
stable secondary structure is not fully formed until recognition is
complete. IDPs use this conformational plasticity to their advan-
tage, forming relatively short-lived complexes in response to vari-
ous cellular stimuli.
The ubiquitous tumor suppressor protein p53 utilizes two
molecular recognition elements in its intrinsically disordered
N-terminal transactivation domain (TAD) to interact with a variety
of cellular targets in response to DNA damage and cellular stress
[27,28]. Structural data exists for many complexes involving the
p53 TAD, including complexes with multiple domains of the tran-
scriptional coactivators CBP/p300 [29–32], MDM2 [33] and MDMX
[34], replication protein A [35], HMGB1 [36], and TFIIH [37]. The
structures reveal that the p53 TAD interacts with its many targets
in different conformations while utilizing similar networks of
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the amphipathic AD1 and AD2 helices (Fig. 1). The AD1 helix medi-
ates the interactions with MDM2 and MDMX [33,34], whereas
interactions via the AD2 helix are critical for binding to replication
protein A, TFIIH, and HMGB1 [35–37]. The p53 TAD relies on con-
tributions from both the AD1 and AD2 helices for interactions with
the TAZ2 and NCBD domains of CBP/p300 [29,31,32]. The AD1 and
AD2 motifs function synergistically to bind the CBP/p300 domains
with high afﬁnity [27]. The isolated AD1 and AD2 motifs differ in
the strength of their interactions, with AD2 binding about
100-fold more tightly to the TAZ1 and TAZ2 domains. As a conse-
quence, the full-length p53 TAD can act as a bridge between
MDM2 and CBP/p300 to form a ternary complex in which AD1 is
bound to MDM2 while AD2 interacts with the TAZ1, TAZ2, KIX,
or NCBD domains of CBP/p300 [27]. This ternary complex plays
an important role in regulating the stability of p53 and in mediat-
ing the response to cellular stress.
2.3. Crosstalk between peptide motifs
While early studies on the interactions between IDPs and their
globular targets generally focused on short peptides due to techni-
cal limitations [7], advances in molecular biology and biophysics
have allowed investigations of interactions involving larger IDP
systems containing multiple interaction sites [10]. These studies
reveal that multiple recognition elements within IDPs do not func-
tion independently, despite their disordered nature. Synergistic
coupling between independent binding sites is a common feature
of IDPs. While individual recognition elements typically interact
with low afﬁnity, multiple tandem interaction sites often con-
tribute to formation of high afﬁnity complexes. For instance, the
intrinsically disordered eukaryotic initiation factor 4E (eIF4E) bind-
ing protein 4E-BP2 binds to eIF4E to regulate cap-dependent trans-
lation initiation. Full-length constructs of 4E-BP2 bind to eIF4E via
a bipartite interface to form a complex with low nanomolar afﬁnity
[38]. However, alteration of either of the two binding motifs by
site-directed mutagenesis or truncation results in enhanced
dynamics at the binding sites and decreased afﬁnity, indicating
that interplay between the binding sites is critical for formation
of a stable complex between eIF4E and 4E-BP2 [38,39].
Additionally, recognition elements that are spatially separated
within the same polypeptide chain have been found to act by both
positively and negatively cooperative mechanisms, suggesting that
IDPs are capable of regulating cellular responses through allosteric
modulation [40]. Theoretical descriptions of allostery suggest that
disorder might even be advantageous for allosteric coupling [41]
and recent examples in the literature support the roles of IDPs in
modulating allostery [27,40–46]. The adenoviral oncoprotein E1AFig. 1. Motifs play a critical role in molecular recognition by p53. Structures of the p53
(middle), the NCBD domain of CBP (right) are shown to illustrate how p53 uses its diffeutilizes two conserved binding motifs in its disordered
N-terminus to interact with numerous cellular targets to hijack
the cell cycle of the host organism and activate transcription of
the viral genome [47]. E1A functions as a molecular hub and inter-
acts with various protein partners depending on the availability of
its binding sites. E1A interacts with both the TAZ2 domain of
CBP/p300 and the pocket domain of the retinoblastoma protein
pRb at spatially separated, non-overlapping binding sites to epige-
netically reprogram the host cell [48,49]. E1A is capable of forming
binary complexes with either TAZ2 or pRb or a ternary complex
with both TAZ2 and pRb, with each complex mediating a different
cellular outcome [42]. Intriguingly, the order of binding events and
occupancy of individual binding sites can either enhance or repress
further interactions through both positive and negative cooperativ-
ity. Through this mechanism E1A is able to efﬁciently disrupt nor-
mal cellular regulation of the host cell and reprogram the cellular
machinery for replication of the viral genome [42].
3. Relationship between disorder and availability of binding
sites
Recent experimental and theoretical descriptions of association
processes involving IDPs illustrate the extreme complexity of these
processes (reviewed in [10,50–52]). A growing body of data shows
that unbound IDPs in the cell do not adopt stable structures;
instead, they are best characterized as ensembles of dynamic struc-
tures that interconvert freely [53–56]. Our knowledge of the exact
nature of the ‘conformational ensembles’ of IDPs and the direct
correlations between conformational ensembles and biological
function remains limited [54,57,58]. Nevertheless, the dynamic
populations of IDPs within the cell are of clear importance to bio-
logical function and will undoubtedly be the focus of numerous
multidisciplinary studies in the future.
The relationship between conformational ensembles of IDPs
and the binding process is also of great interest from both mecha-
nistic and functional standpoints. A better understanding of how
the conformational ensemble of a free IDP affects its interactions
with molecular targets will greatly enhance our understanding of
how IDPs carry out their biological functions. The inherent ﬂexibil-
ity of disordered regions helps keep binding motifs accessible until
the correct target has been located. These properties give rise to
complex binding mechanisms that are critical to cellular function.
3.1. Coupled folding and binding
The transition from a disordered state in solution to a more
ordered state upon target binding is a common feature in IDP func-
tion [5]. While a consensus mechanism for coupled folding andtransactivation domain (blue) in complex with MDMX (left), replication protein A
rent interaction motifs to bind to multiple proteins.
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nisms have been proposed and evidence has been obtained in sup-
port of each (Fig. 2) [7]. At one extreme is the induced folding
mechanism, which assumes that folding occurs after association
of the IDP with its target. At the other extreme is the conforma-
tional selection mechanism, in which the bound conformation is
populated in the conformational ensemble of the unbound IDP
and is selected from the ensemble for binding to the target protein.
However, the more likely scenario is that most IDPs will associate
with their targets by a combination of these extreme mechanisms
[59,60].
3.2. Role of pre-formed structure
Characterization of the conformational ensembles of IDPs
reveals that free IDPs adopt varying populations of pre-formed sec-
ondary structural elements. It has been proposed that pre-formed
structural elements are advantageous for target recognition, but
the correlation between the populations of structural elements in
the conformational ensemble of free IDPs and the behavior of
IDPs in their bound states remains elusive [61,62]. Several recent
examples from the literature suggest that the population of
pre-formed secondary structural elements in the conformational
ensemble of free IDPs does not inﬂuence association kinetics or
binding mechanism [63–67]. In each of these cases, folding of the
IDP does not depend on the presence of pre-formed structure in
the conformational ensemble but is instead initiated by early bind-
ing events. However, other studies clearly indicate that the popu-
lation of pre-formed structural elements in the conformational
ensemble directly inﬂuences binding [68–71], suggesting that the
exact mechanism of coupled folding and binding differs for differ-
ent IDPs.
NMR relaxation dispersion studies of coupled folding and bind-
ing processes have been particularly useful for describing the con-
formational transitions that occur during molecular recognition by
IDPs [67,71,72]. A recent study on binding of the intrinsically dis-
ordered C-terminus of the Sendai virus nucleoprotein (NT) to its
partially folded phosphoprotein (PX) partner demonstrates the
value of the atomic level resolution provided by NMR spectroscopy
when investigating complex coupled folding and binding pro-
cesses. Measurements of relaxation data for multiple nuclei (15N,
1HN, and 13CO) in the disordered nucleoprotein in complex with
varying sub-stoichiometric amounts of PX allowed for detailed
insights into the folding process and the conformational ensemble
formed early in the binding process [71]. In the case of the NT:PX
interaction, partially helical conformations are present in the con-
formational ensemble of unbound NT, and initial interactions
between these partially helical NT substates and PX directly inﬂu-
ence formation of stable complexes [71]. Binding occurs in a
two-step process by way of a disordered intermediate, whichFig. 2. Schematic representation of proposed mechanisms for coupled folding and
binding processes of IDPs. The induced folding mechanism suggests that initial
binding events trigger the IDP to adopt its folded conformation in complex with its
target, whereas the conformational selection mechanism requires some population
of the free IDP to adopt its structured conformation in the unbound state. Examples
from the literature support both of the proposed mechanisms.rearranges slowly to form the ﬁnal folded complex [71,73].
Interestingly, the slow step on the binding and folding pathway
is associated with motions of the PX target to allow optimal dock-
ing of the NT helix [71]. It is to be hoped that relaxation dispersion
studies will be performed on a wide range of IDP systems to
expand our knowledge of the factors that determine the mecha-
nism of molecular recognition.
Despite the role of pre-formed structural elements in enhancing
binding or accelerating some coupled folding and binding processes
[68–71], increasing the population of partially structured states in
the unbound IDP does not necessarily enhance biological function.
The disordered N-terminal transactivation domain of p53 relies on
an amphipathic helical motif, the AD1 motif described above, to
interact with the E3 ubiquitin ligase MDM2. In isolation, the AD1
motif, which is ﬂanked by conserved proline residues at both ends,
has only a weak propensity to form helix. Mutation of a proline resi-
due C-terminal to the MDM2-binding motif substantially increases
both the residual helicity and the binding afﬁnity for MDM2.
However, the increased afﬁnity of the mutant p53 has a drastic
effect on transcription of target genes and on the lifetime of p53
in the cell, indicating that the intrinsic helicity of the transactiva-
tion domain of p53 is ﬁnely tuned for proper cellular function [68].
3.3. Disorder enhances the accessibility of binding sites
Another beneﬁt of disorder is that an IDP can utilize its ﬂexibil-
ity to adopt different conformations in complex with different cel-
lular partners. An individual IDP can participate in early,
non-speciﬁc molecular recognition events without a signiﬁcant
energetic penalty, thus keeping its binding motifs accessible to
respond to various cellular stimuli.
By remaining disordered in the unbound state, IDPs are able to
select their targets based on environmental cues. The intrinsically
disordered C-terminal transactivation domain (CTAD) of the
hypoxia inducible factor-1a (HIF-1a) plays an important role in
activating transcription of genes that are critical for cell survival
under low cellular oxygen concentrations through interactions
with the TAZ1 domain of the transcriptional coactivators
CBP/p300 [74]. Under normoxic conditions, a single asparagine
residue (Asn803) in the HIF-1a CTAD is hydroxylated by the aspar-
agine hydroxylase FIH to impair binding to the TAZ1 domain of
CBP/p300 [75,76]. However, under hypoxic conditions, Asn803 is
not hydroxylated and the HIF-1a CTAD is capable of interacting
with TAZ1 with low nanomolar afﬁnity. The HIF-1a CTAD is disor-
dered in solution but forms three helices upon TAZ1 binding, with
Asn803 located within one of these helical regions (Fig. 3left)
[77,78]. Interestingly, the same region of HIF-1a adopts a markedly
different conformation in complex with FIH, with the region ﬂank-
ing Asn803 binding to FIH in an extended structure in order to
place the asparagine side chain into the FIH active site [75]
(Fig. 3right). In this case, HIF-1a utilizes conformational plasticity
to function as a molecular switch in response to changes in oxygen
levels in the cellular milieu.
4. Post-translational modiﬁcations provide an exquisite level of
control
A critical property of IDPs that relates to their central role in cel-
lular signaling is their propensity for post-translational modiﬁca-
tion. There are over 300 known types of post-translational
modiﬁcations (PTMs) in the eukaryotic genome [79], and studies
of both IDPs and globular proteins suggest that these modiﬁcations
are highly abundant, with densities potentially as high as one PTM
for every 10 residues [13]. Post-translational modiﬁcation sites are
abundant in IDPs, and the observation that the majority of known
phosphorylation sites are found in intrinsically disordered regions
Fig. 3. The HIF-1a transactivation domain can adopt multiple structures. HIF-1a binds to the TAZ1 domain of CBP in a helical conformation (left; for clarity, only one of the
three helices formed in HIF-1a is shown). The same region of HIF-1a binds to FIH in an extended conformation (right). Residues 795–805 of the HIF-1a C-terminal
transactivation domain are shown in green. The sidechain of asparagine 803 is highlighted in orange.
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of IDPs in both their free and bound states increases their accessi-
bility not only for molecular recognition but also to modifying
enzymes.
Post-translational modiﬁcation of IDPs can play a major role in
modulating their cellular functions. PTMs within binding motifs
can function as on/off switches for a speciﬁc molecular interaction
[14]. Accumulation of multiple PTMs can dramatically alter the
electrostatics of an IDP to either weaken or strengthen interactions
with its cellular partners. PTMs are also capable of modulating the
conformational ensembles of IDPs, both free in solution and in
complex with their binding partners [10]. It is clear that
post-translational modiﬁcation of IDPs enables strategic, tunable,
and reversible regulation of their function in the cell.
4.1. Disorder facilitates access to modifying enzymes
For a protein to be post-translationally modiﬁed, its PTM sites
must be fully accessible to modifying enzymes. Potential modiﬁca-
tion sites that are obscured by structural elements are usually inac-
cessible to modifying enzymes and thus post-translational
modiﬁcations are frequently found in disordered regions, either in
the unbound IDP or in regions that remain disordered in the IDP
complexes [54]. This is certainly the case for the disordered trans-
activation domain of HIF-1a, which necessarily adopts a relatively
extended structure when bound to FIH for hydroxylation [75].
Post-translational modiﬁcations can play important roles in
controlling the afﬁnity and the order of binding events. For exam-
ple, the afﬁnity of the kinase inducible domain (KID) of the
cyclic-AMP responsive transcription factor CREB for the KIX
domain of CBP/p300 is enhanced 100-fold by phosphorylation at
a single serine residue by protein kinase A [81,82]. In the
amino-terminal disordered transactivation domain of p53, phos-
phorylation of a single threonine residue (Thr18) as part of a sig-
naling cascade impairs binding to the E3 ubiquitin ligase HDM2
[83,84]. In both of these cases, a single phosphorylation event is
sufﬁcient for regulation of important cellular processes, highlight-
ing the exquisite sensitivity and responsiveness of IDPs to
post-translational modiﬁcations.
4.2. Accumulation of post-translational modiﬁcations can enhance
cellular responses
While a single post-translational modiﬁcation can be a sufﬁ-
cient signal in regulatory processes, PTM sites are often located
in clusters within IDPs [85]. Multiple PTMs in a disordered regioncan act synergistically to ensure signaling ﬁdelity in crowded cel-
lular environments. Accumulation of PTMs in an IDP could signiﬁ-
cantly alter the charge distribution within an IDP and hence its
conformational ensemble [86]. Additionally, multiple PTMs in a
given region could change the electrostatic properties of the IDP
to directly inﬂuence its association with cellular targets.
The disordered N-terminal transactivation domain (TAD) of p53
contains nine known phosphorylation sites (Fig. 4). While the exact
timing of phosphorylation events initiated by cellular stress is not
yet known, simultaneous phosphorylation of two to four sites
within the p53 TAD has been detected in cell extracts [87]. In
unstressed cells, p53 forms a ternary complex with CBP/p300
and HDM2. Phosphorylation of p53 occurs in response to DNA
damage, and phosphorylation of speciﬁc sites within the p53
TAD incrementally modiﬁes the ability of p53 to interact with its
cellular partners [27]. Interestingly, increasing the number of
phosphorylation events on the p53 NTAD directly increases the
afﬁnity of the p53 TAD for the TAZ1, TAZ2, and KIX domains of
CBP/p300, with each successive phosphorylation having an addi-
tive effect on the measured binding afﬁnity [83]. In the case of
p53, post-translational modiﬁcations play an important role in
ﬁne-tuning the binding afﬁnity for its various cellular partners.
4.3. Modiﬁcations can induce structural changes
In addition to their ability to enhance or disrupt interactions
with other proteins, post-translational modiﬁcations can also
change the conformations of IDPs themselves to either favor or dis-
favor molecular recognition processes. Incorporation of PTMs into
free IDPs can alter the distribution of states within the conforma-
tional ensemble, in effect modulating the functional capabilities
of the protein.
Recent studies have demonstrated that post-translational mod-
iﬁcations affect the conformational and structural properties of
IDPs in isolation and in molecular complexes. PTMs are capable
of disrupting molecular interactions and inducing distinct confor-
mational changes [88,89], stabilizing secondary structural ele-
ments in the conformational ensemble [90], or even inducing
disorder-to-order transitions to produce partially folded conforma-
tions of IDPs in solution [91]. In its unphosphorylated state the dis-
ordered protein 4E-BP2 undergoes a disorder-to-order transition
upon binding eIF4E for regulation of cap-dependent translation ini-
tiation [38,92,93]. Phosphorylation of 4E-BP2 at multiple sites
weakens its afﬁnity for eIF4E. The loss of afﬁnity of the phosphory-
lated form of 4E-BP2 can be attributed to its structural properties
in solution. Free 4E-BP2 adopts a stable, partially folded structure
Fig. 4. Sequence of the amino-terminal transactivation domain of p53. Known phosphorylation sites are mapped onto the primary sequence of human p53 in red lettering.
The locations of the amphipathic AD1 and AD2 binding motifs are shown below the sequence.
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canonical binding motifs and thus reducing its ability to interact
with eIF4E [91]. In this system, successful molecular recognition
requires a sufﬁcient amount of disorder. Stabilization of the par-
tially folded conformation of 4E-BP2 through phosphorylation is
a robust mechanism for regulating the function of 4E-BP2 in the
cell.
5. Future perspectives
The importance of intrinsically disordered proteins in biology
and medicine cannot be understated and rapidly expanding inves-
tigations of IDPs both in vitro and in vivo continue to enhance our
understanding of the important roles of IDPs in cellular regulation
and signaling. It is clear that IDPs utilize a wide range of strategies
to accomplish their biological tasks, with their disordered nature
providing unparalleled complexity but also multiple opportunities
and mechanisms for dynamic regulation of the cell, many of which
have been outlined in this review.
Recent technical advances have led to new advances in under-
standing the diverse mechanisms of IDPs. Due to technical limita-
tions, early studies of IDPs were often limited to experiments
involving short peptides to mimic the disordered regions of larger,
multi-domain proteins. Full-length eukaryotic proteins containing
disordered and structured domains are often quite unstable and
can be difﬁcult to purify, even from eukaryotic systems, due to
their aggregation propensities and sensitivity to proteolytic degra-
dation. Improvements in eukaryotic expression systems [94] and
screening technologies to enable rapid determination of soluble
protein constructs [95] have led to signiﬁcant advances in expres-
sion and puriﬁcation of multi-domain disordered proteins.
Cell-free expression methods also have the potential to improve
the yield of intact, multi-domain proteins from both prokaryotic
and eukaryotic systems [96,97]. In the case of NMR spectroscopy,
which requires isotopic labeling, selective labeling techniques have
greatly improved our ability to characterize molecular interactions
in larger systems where the combination of structured and disor-
dered domains can be challenging. Chemical strategies for selective
incorporation of NMR active isotopes at speciﬁc sites in the
polypeptide allow for enhanced sensitivity and reduced spectral
overlap in larger systems [98,99]. Intein-based ligation methods
promise to be extremely useful by allowing isotopic labeling of
speciﬁc segments of larger polypeptides [100]. The ability to char-
acterize the role of intrinsically disordered regions within the con-
text of the full-length proteins will provide new insights into the
relationship between local, intramolecular interactions within
the conformational ensembles and the biological functions of IDPs.
Studies of IDPs in the crowded cellular environment will also be
highly important. While once a source of controversy, it is now
widely accepted that IDPs can exist in disordered states in the cel-
lular context [56]. Nevertheless, many more studies and new tech-
nologies are needed to advance our understanding of how IDPs
carry out their biological functions in vivo. Fluorescence-based
methods have shown great promise in this regard, with
single-molecule techniques providing exquisite sensitivity for
detecting transient interactions and rapid signaling processes
within the cell [101–103]. NMR studies of proteins in whole cellsand cell extracts are in their early stages but initial
proof-of-principle studies [104] suggest that these methods could
be extremely useful for quantiﬁcation and characterization of IDP
conformational ensembles, elucidation of coupled folding and
binding processes, and analysis of responses of IDPs to
post-translational modiﬁcations at atomic level detail.
Due to their involvement in key signaling pathways and their
frequent association with disease [6] IDPs are also becoming the
focus of drug development efforts. Most of the available pharma-
ceuticals have been designed to target speciﬁc classes of proteins
with well-deﬁned three-dimensional structures [105,106]. This
approach to drug design is often limited by the properties of the
target molecules themselves. Typically, small molecule inhibitors
are designed to disrupt protein–protein interactions by binding
in small, hydrophobic pockets. However, the binding interfaces
that the inhibitors are intended to target often represent only a
very small region within a much larger binding surface and thus
are likely to be occluded by the deﬁned structural elements of
the target macromolecules, reducing the efﬁcacy of the drug. In
contrast, IDPs bind to globular proteins via discrete structural
motifs linked by disordered regions. The intrinsic ﬂexibility and
speciﬁcity of the interaction between an IDP and its target proteins
provides a novel approach for therapeutic design. Small molecules,
as well as stapled peptides that are designed to mimic the bound
conformations of IDPs have been shown to effectively target the
interactions between IDPs and globular targets [107–111].
Additionally, the IDPs themselves could potentially be targeted to
block speciﬁc interactions [112,113]. Our expanding knowledge
of the properties of IDPs and the mechanisms by which they func-
tion in the cell will greatly inform future drug discovery efforts.
In summary, intrinsically disordered proteins play numerous,
essential roles in cellular processes. Further studies to improve
our understanding of how IDPs function in the cellular context will
be of extreme importance for advancing our understanding of cel-
lular signaling and regulation. Great advances have already been
made but exciting new areas of research involving IDPs are
expanding our views of the structure–function paradigm and
revealing that signiﬁcant levels of disorder are advantageous and
even required for numerous aspects of cellular function.
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